drugset / Trial / NCT03035422
Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia
Completed
24 enrolled
Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
NaSingle-groupOpen-labelOther
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in acute myeloid leukemia (AML) or refractory multiple relapses after chemotherapy. However, all patients with an indication of allo-HSC can not benefit because of two limitations: the toxicity of the treatment and graft shortage available.
Timeline
- Start
- 2018-01-15
- Primary completion
- 2021-12-18
- Completion
- 2021-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 400 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
| Subject | Thiotepa | Other / unclassified | 5 mg/kg | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | — |
| Background | Cyclosporine | Peptide | 3 mg/kg | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 30 mg/kg | — |